MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-29-2026
Amarin Corporation plc Total Assets 2011-2026 | AMRN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Amarin Corporation plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 671 M | 685 M | 832 M | 886 M | 1.07 B | 966 M | 882 M | 386 M | 162 M | 167 M | 173 M | 171 M | 252 M | 311 M | 126 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 B | 126 M | 516 M |
Quarterly Total Assets Amarin Corporation plc
| 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 646 M | 671 M | 670 M | 656 M | 685 M | 751 M | 800 M | 790 M | 832 M | 839 M | 860 M | 860 M | 886 M | 908 M | - | 974 M | 1.07 B | 1.04 B | 1.04 B | 990 M | 966 M | 966 M | 966 M | 966 M | 882 M | 882 M | 882 M | 882 M | 386 M | 386 M | 386 M | 386 M | 162 M | 162 M | 162 M | 162 M | 167 M | 167 M | 167 M | 167 M | 173 M | 173 M | 173 M | 172 M | 171 M | 171 M | 171 M | 171 M | 252 M | 252 M | 252 M | 252 M | 311 M | 311 M | 311 M | 311 M | 126 M | 126 M | 126 M | 126 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 B | 126 M | 514 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 5.5 | 4.47 % | $ 878 M |  Britain |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
22 B | $ 96.05 | -3.33 % | $ 27.2 B | Germany |
 |
Cerus Corporation
CERS
|
222 M | $ 2.71 | -0.55 % | $ 517 M | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Cardiff Oncology
CRDF
|
61.9 M | $ 1.68 | 1.82 % | $ 112 M | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B | Britain |
 |
Edesa Biotech
EDSA
|
3.81 M | $ 15.8 | -1.92 % | $ 50.5 M | USA |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Evogene Ltd.
EVGN
|
20 M | $ 0.75 | -0.13 % | $ 27.9 M | Israel |
 |
CymaBay Therapeutics
CBAY
|
435 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
426 M | - | - | $ 3.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
35 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
18.6 M | $ 0.58 | -1.56 % | $ 2.5 M | Israel |
 |
Genmab A/S
GMAB
|
21.1 B | $ 27.1 | 0.2 % | $ 16.8 B |  Danmark |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.56 | 1.67 % | $ 3.74 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
474 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 8.21 | -0.24 % | $ 6.83 B |  Spain |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.45 | 3.92 % | $ 5.68 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
38.8 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
21.1 M | - | -5.68 % | $ 8.28 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.27 B | $ 32.83 | 0.74 % | $ 1.89 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |